Close

Acorda Therapeutics (ACOR) Reports Q3 EPS of 28c

October 30, 2014 8:02 AM EDT

Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of $0.28, may not compare to the analyst estimate of $0.05. Revenue for the quarter came in at $106 million versus the consensus estimate of $94.7 million.

It raised full year 2014 guidance for AMPYRA net revenue from $328-$335 million to $345-$350 million

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings